AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections

The CHMP followed recent EMA guidance to take a flexible approach to drugs against multi-resistant pathogens when recommending approval for AstraZeneca’s latest antibacterial Zavicefta.

Lactobacillus bacteria

AstraZeneca PLC’s new antibacterial, Zavicefta (ceftazidime plus avibactam), has been recommended for approval in the EU by the top advisory panel, the Committee for Medicinal Products for Human Use (CHMP), for use in the treatment of patients infected with multi-drug resistant bacteria, so-called “superbugs”, as well as several other severe bacterial infections.

The committee recommended approval for infections caused by multi-drug resistant pathogens on the basis of a limited set of data,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip